Try the modernized beta website. Learn more about the modernization effort.
Working… Menu
Trial record 1 of 1 for:    capmatu | France
Previous Study | Return to List | Next Study

RW Effectiveness of Capmatinib in Advanced MET-dysregulated NSCLC Included in the French Compassionate Use Program (ATU) (CapmATU)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT05154344
Recruitment Status : Completed
First Posted : December 13, 2021
Last Update Posted : February 25, 2022
Information provided by (Responsible Party):
Intergroupe Francophone de Cancerologie Thoracique

Brief Summary:
CapmATU study will evaluate time to treatment failure, progression-free survival, overall survival, best response and safety in patients with advanced MET-dysregulated non-small cell lung cancer who received capmatinib as part of an expanded access program. Those outcomes will be correlated to clinical, pathological, and radiological characteristics of patients.

Condition or disease Intervention/treatment
MET Alterations Non Small Cell Lung Cancer METex14 Mutations Drug: Capmatinib

Detailed Description:

Capmatinib has been approved in the USA and Japan. In France, a compassionate use for capmatinib has been approved in June 2019 for patients with MET alterations, including METex14 mutations and MET amplification. In March 2021, 204 patients are or have been treated with compassionate use capmatinib as part of this program, most of them (n=175) harboring a METex14 mutation.

So far, data on activity and safety of new-generation MET TKIs are still sparse and only based on prospective clinical studies. The CapmATU study is a unique opportunity to describe patients' characteristics and outcomes, and confirm effectiveness of capmatinib in a large cohort of METex14 NSCLC. Moreover, it will provide original real-world evidence (RWE). RWE can be used in oncology to further characterize the safety and efficacy of drugs in the post-marketing setting. This may include confirmation of clinical benefit for regulatory purposes, expansion of labeling claims to new indications, testing of alternate doses and schedules of drugs, and assessment of drug activity in biomarker-defined subgroups and other special populations. This may be even more important in the context of METex14 NSCLC patients since no real world data with new generation MET TKIs have been reported so far. Indeed, this study will allow to determine whether the antitumor activity of capmatinib reported in the GEOMETRY-MONO-1 study can be observed in less selected patients. Given the older age and associated comorbidities of METex14 NSCLC patients, most of them may not be eligible to a clinical trial, thus emphasizing the need for real-world evidence. Finally, the biological part of this study (CapmATU-BIO) will offer opportunity to identify biomarkers of sensitivity or acquired resistance to capmatinib, which is a poorly explored field of research so far.

In this context, the objectives of this non-interventional retrospective French population-base study are to describe the characteristics of patients with MET-dysregulated NSCLC, assess effectiveness and safety of capmatinib in these patients and identify biomarkers of benefit from capmatinib.

Layout table for study information
Study Type : Observational
Actual Enrollment : 182 participants
Observational Model: Cohort
Time Perspective: Retrospective
Official Title: Real World Effectiveness of Capmatinib in Patients With Advanced MET-dysregulated NSCLC Included in the French Compassionate Use Program (ATU)
Actual Study Start Date : November 29, 2021
Actual Primary Completion Date : February 1, 2022
Actual Study Completion Date : February 1, 2022

Resource links provided by the National Library of Medicine

Drug Information available for: Capmatinib

Intervention Details:
  • Drug: Capmatinib
    Available through expanded access
    Other Name: Tabrecta

Primary Outcome Measures :
  1. time to treatment failure [ Time Frame: 2 years ]
    time to treatment failure in patients with advanced NSCLC harboring a METex14 mutation receiving capmatinib as part of the French compassionate use program (ATU)

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
Patients with advanced NSCLC harboring a METex14 mutation receiving capmatinib as part of the French compassionate use program (ATU).

Inclusion Criteria:

  • Patients with histologically or cytologically confirmed locally advanced or metastatic NSCLC (Stage IIIB or IV accordingly to American Joint Committee on Cancer [AJCC] classification) at time of capmatinib initiation
  • Presence of a MET dysregulation diagnosed on tumor sample and/or on liquid biopsy
  • Patients who were informed about the study and accepted for their data to be collected.
  • Patients who received at least one dose of treatment with capmatinib as part of the compassionate use program (ATU), whatever the line of treatment.
  • Selection period spans from June 1st 2019 (date of start of French ATU) until August 31st 2021 for first dose of capmatinib.
  • Age >18 y

Exclusion Criteria:

  • Patients enrolled in a clinical trial assessing treatment with capmatinib. (ATU was granted to patients unable to meet eligibility criteria for on-going recruiting trials, unable to participate to other clinical trials, or because other medical interventions were not considered appropriate or acceptable).
  • Patients who were included in the French Early Access Program (ATU program) but did not receive any capmatinib treatment.
  • Patients who have expressed explicit refusal to collect his or her data
  • Patients with a psychiatric history that hinders the comprehension of the information leaflet
  • Patients under curatorship or guardianship
  • Unability to obtain data collection

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT05154344

Layout table for location information
Lille, France
Tours, France
Sponsors and Collaborators
Intergroupe Francophone de Cancerologie Thoracique
Layout table for additonal information
Responsible Party: Intergroupe Francophone de Cancerologie Thoracique Identifier: NCT05154344    
Other Study ID Numbers: IFCT-2104
First Posted: December 13, 2021    Key Record Dates
Last Update Posted: February 25, 2022
Last Verified: November 2021
Keywords provided by Intergroupe Francophone de Cancerologie Thoracique:
Expanded access program
Additional relevant MeSH terms:
Layout table for MeSH terms
Carcinoma, Non-Small-Cell Lung
Carcinoma, Bronchogenic
Bronchial Neoplasms
Lung Neoplasms
Respiratory Tract Neoplasms
Thoracic Neoplasms
Neoplasms by Site
Lung Diseases
Respiratory Tract Diseases